Acorda Therapeutics, Inc. (ACOR)
(Delayed Data from NSDQ)
$11.74 USD
+1.16 (10.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.74 USD
+1.16 (10.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down
by Zacks Equity Research
Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.
Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line
by Zacks Equity Research
Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.
Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More
by Arpita Dutt
Key highlights in the biotech sector include mixed data from Cara (CARA) and regulatory updates from companies like BioMarin.
Acorda Files NDA for Parkinson's Disease Candidate Inbrija
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.
Acorda Presents Phase III Data on PD Candidate CVT-301
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) presented data from a phase III study SPAN-PD, evaluating its late stage candidate CVT-301 (levodopa inhalation powder) at the International Congress of Parkinson's Disease and Movement Disorders (MDS).
Why Is Acorda (ACOR) Down 8.4% Since the Last Earnings Report?
by Zacks Equity Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen's Fampyra Conditional Approval Converted to Standard
by Zacks Equity Research
Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.
Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents.
Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) recently announced plans to reduce its workforce by approximately 20%.
Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge
by Zacks Equity Research
Acorda Therapeutics, Inc.???s (ACOR) shares were down almost 21.5% after the U.S. District Court for the District of Delaware invalidated four patents of its key multiple sclerosis drug, Ampyra.
Acorda Presents Data for Parkinson's Candidate CVT-301
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson's disease.
Alkermes Starts Phase III Study to Treat Multiple Sclerosis
by Zacks Equity Research
Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.
Why Is Acorda (ACOR) Up 10.6% Since the Last Earnings Report?
by Zacks Equity Research
Acorda Therapeutics (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
by Arpita Dutt
The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.
Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise
by Zacks Equity Research
U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of Acorda's key growth driver, Ampyra.
Acorda Therapeutics (ACOR) Jumps: Stock Adds 6.5% in Session
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) moved big last session, as its shares rose above 6% on the day.
Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options
by Zacks Equity Research
Investors in Acorda Therapeutics, Inc. (ACOR) need to pay close attention to the stock based on moves in the options market lately.
Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) reported loss of 7 cents per share in the fourth quarter of 2016 (including the impact of stock-based compensation expenses), narrower than the Zacks Consensus Estimate of a loss of 18 cents.
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data
by Arpita Dutt
Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.
Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16.
Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.
Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) moved big last session, as its shares rose almost 21% on the day.
Can Prothena (PRTA) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.